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Association between metformin dose and vitamin
B12 deﬁciency in patients with type 2 diabetes
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Abstract
Background:Metformin can cause serum vitamin B12 deﬁciency, but studies on the inﬂuence of its duration and dose are lacking.
We investigated vitamin B12 deﬁciency in patients with type 2 diabetes using metformin, in conjunction with other related factors.
Method: This cross-sectional study included 1111 patients with type 2 diabetes who took metformin for at least 6 months. Serum
vitamin B12 levels were quantiﬁed using a competitive-binding immunoenzymatic assay, and vitamin B12 deﬁciency was deﬁned as
serum B12<300pg/mL. Information on metformin use and confounding variables were collected from records or questionnaires and
interviews.
Result: Serum vitamin B12 deﬁciency occurred in 22.2% of patients (n=247). After adjusting for confounders, a 1mg increase in
daily metformin dose was associated with a 0.142pg/mL decrease in vitamin B12 (P< .001). Compared with a daily dose of<1000
mg, the adjusted odds ratios for 1000 to 1500, 1500 to 2000, and ≥2000mg metformin were 1.72 (P= .080), 3.34 (P< .001), and
8.67 (P< .001), respectively. Vitamin B12 deﬁciency occurred less often in patients taking multivitamins (odds ratio 0.23; P< .001).
After adjusting for confounding factors, there was no correlation between B12 deﬁciency and duration of metformin use. Serum
homocysteine levels showed signiﬁcant negative correlation with vitamin B12.
Conclusion: Metformin at ≥1500mg/d could be a major factor related to vitamin B12 deﬁciency, whereas concurrent
supplementation of multivitamins may potentially protect against the deﬁciency. Serum homocysteine levels were negatively
correlated with vitamin B12 levels, suggesting that B12 deﬁciency due to metformin use may occur at the tissue level. However, this
hypothesis will require further study.
Abbreviations: ALT = alanine aminotransferase, AST = aspartate aminotransferase, AUC = area under the curve, CI =
conﬁdence interval, DPN = diabetic peripheral neuropathy, GFR = glomerular ﬁltration rate, HbA1c = glycated hemoglobin, MCV =
mean corpuscular volume, OR = odds ratio, ROC = receiver operator characteristic.
Keywords: homocysteine, metformin, multivitamin, vitamin B12 deﬁciency
1. Introduction
Metformin as a ﬁrst-line oral treatment for hyperglycemia in
diabetes is generally regarded as having few side effects.[1]
However, since Berchtold et al ﬁrst reported in 1969 that
metformin could cause vitamin B12 deﬁciency by reducing
vitamin B12 absorption in the gastrointestinal tract, such ﬁndings
have been constantly published.[2] It has been reported that an
average of 6% to 30% of patients could show vitamin B12
deﬁciency due to metformin use.[3,4] In addition, some studies
have reported that serum vitamin B12 levels were inversely
related to the duration and dose of metformin use.[5–8] Since large
prospective studies have clariﬁed this relationship recently,[9,10]
the 2017 American Diabetes Association treatment guidelines
now recommend regular monitoring of vitamin B12 levels in
patients with diabetes taking metformin.[11]
Meanwhile, serum vitamin B12 may be an unreliable marker
for overall vitamin B12 deﬁciency because of the variability in
measurement methods.[12] Homocysteine is a key component in
the one-carbon pathway of methionine metabolism which plays
an important role in DNAmethylation, and is involved in various
intracellular vitamin B12 reactions.[1,13] An increase in homo-
cysteine is known to be related to an increased risk of
cardiovascular diseases, cognitive disorders, cancer, chronic
kidney disease, and other chronic diseases, and is often caused by
vitamin B12 deﬁciency. Therefore, increased homocysteine levels
in patients with serum vitamin B12 deﬁciency can more
accurately predict vitamin B12 deﬁciency in true tissues.[1,13]
Many studies have investigated homocysteine increases in
patients taking metformin, but there is still controversy on the
conclusions of the studies.[14,15]
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Although the clinical signiﬁcance of metformin-induced
vitamin B12 deﬁciency is controversial, anemia and peripheral
nerve damage are typically attributed symptoms.[1,16] If periph-
eral nerve damage is not adequately treated, diabetic peripheral
neuropathy (DPN) may be exacerbated, leading to serious and
permanent nerve damage.[17] As such, it is clinically advisable to
ensure that B12 deﬁciency does not develop under metformin
treatment.
Comparatively lower amounts of meat are consumed in Asian
countries than in Western nations, suggesting a higher risk of
vitamin B12 deﬁciency, but few studies have considered the
impact of duration and dose of metformin use in this context. We
investigated the prevalence of vitamin B12 deﬁciency among
Korean patients with type 2 diabetes under long-term metformin
treatment, and examined how the period and dose of metformin
affected B12 deﬁciency. We further investigated whether
metformin-induced B12 deﬁciency in the serum could indicate
tissue deﬁciency by also measuring serum homocysteine.
2. Method
2.1. Participants
The study protocol conformed to the ethical guidelines of the
Declaration of Helsinki and was approved by the institutional
review board at Yongin Severance Hospital, Yonsei University
College of Medicine, Korea (protocol No. 9-2017-0003), and all
participants provided written informed consent. In this cross-
sectional study, patients with type 2 diabetes who took
metformin for at least 6 months and visited the Yongin Severance
Hospital outpatient clinic between June 2017 and April 2018
were considered for enrollment. Patients with a history of
gastrectomy, colectomy, inﬂammatory bowel disease, or perni-
cious anemia were excluded. We further excluded patients with
acute illness characterized as severe infection, cancer or acute
coronary syndrome within the last 3 months, as well as serious
organ damage characterized by liver cirrhosis, aspartate
aminotransferase (AST) or alanine aminotransferase (ALT) ≥3
times the upper limit of the normal range, estimated glomerular
ﬁltration rate (GFR) <30mL/min/1.73m2, or symptoms of heart
failure. Patients with hematological disorders other than anemia,
pregnant women, and vegetarian patients were also excluded. Of
the 2933 patients with diabetes who visited the outpatient clinic
during the study period, 1131 adult patients, who were deemed
suitable for the inclusion criteria and agreed to participate in the
study, were evaluated again through detailed review of medical
records and laboratory tests. In the end, 1111 patients were
ﬁnally enrolled in the study (Fig. 1). The 1111 patients were
between 20 to 85 years of age, with a mean age of 59.5 ± 10.9
years, and 58.1% (645 patients) were male. The mean duration
of diabetes was 10.5±6.9 years, and the mean duration of
metformin use was 10.1±7.0 years (range of 0.5–45 years), with
a mean daily dose of 1339±479mg.
2.2. Study methods
Participants underwent basic blood tests at study registration,
and also took questionnaires on neuropathy, supplement drug
histories, as well as alcohol consumption and smoking habits.
The participants’ medical records and past prescriptions were
carefully reviewed during the study period by researchers. Blood
and urine samples were collected in a fasting state to measure
Eligibility assessed (n= 1,131) 
Enrolled (n= 1,111)
Excluded (n=20)
Gastrectomy/ colectomy (n= 10)
Recent malignancy (n= 5)
Liver diseases (n= 3)
Folate deficiency (n= 2)
Vitamin B12 ≤ 300 pg/mL 
(n= 247)
Vitamin B12 > 300 pg/mL 
(n= 864)
Total patients of diabetes (n= 2,933) 
Figure 1. Study ﬂow chart.
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serum vitamin B12, serum folic acid, serum homocysteine,
glucose, insulin, glycated hemoglobin (HbA1c), hemoglobin,
mean corpuscular volume (MCV), AST, ALT, creatinine, total
cholesterol, triglycerides, high-density lipoprotein cholesterol,
low-density lipoprotein cholesterol, and urine albumin-to-
creatinine ratios (ACR). Physical examinations of height, weight,
and blood pressure were also performed. Hypertension was
deﬁned as systolic blood pressure≥140mmHg or diastolic blood
pressure≥90mmHg, or use of any antihypertensive medications.
Cardiovascular disease was deﬁned as a history of coronary heart
disease, stroke, or peripheral arterial disease conﬁrmed by a
specialist. Diabetic retinopathy was noted based on patient
records, or in some cases afﬁrmed by a specialist during study
registration. Diabetic neuropathy was deﬁned as having been
previously diagnosed with DPN, taking relevant medication, or
exceeding 2 points in a questionnaire using the Michigan
Neuropathy Screening Instrument.[18] Time elapsed since initial
diagnosis of diabetes and duration and dose of metformin use
were recorded following a review of medical records. If a patient
had discontinued metformin use for longer than 6 months, the
duration of metformin treatment was counted from when it was
resumed. The daily dose of metformin was calculated as the mean
dose taken over the last 6 months. Additional drug histories,
drinking habits, and smoking habits were collected either from
individual questionnaire or from medical records within the last
year. Use of multivitamins, calcium supplements, histamine-2
receptor blockers, and proton pump inhibitors was noted if taken
continuously for at least 6 months. The average amount of
alcohol consumed weekly was calculated, and 98g per week was
used as a guideline threshold limit for moderate drinking.[19]
2.3. Laboratory testing
Vitamin B12 levels were measured by competitive-binding
immunoenzymatic assays using an Unicel DxI 800 analyzer
(Beckman Coulter, Inc., CA). Assay sensitivity was 50pg/mL, and
inter-assay coefﬁcient of variation was <11.4% at serum
concentrations of 88 to 975pg/mL. In this study, biochemical
vitaminB12deﬁciencywas deﬁned as serumB12<300pg/mL, not
accompanied by serum folic acid deﬁciency.[1,20] Based on this
distinction, patients were categorized as B12-deﬁcient or normal,
and the clinical characteristics of the 2 groups were compared.
Serum folic acid deﬁciency was deﬁned as <4ng/mL.[1] Anemia
was deﬁned as hemoglobin <13g/dL for men and <12g/dL for
women, based on the World Health Organization guidelines.[21]
The homeostasis model of assessment-insulin resistance was
calculated using the following equation: fasting glucose (mg/dL)
fasting insulin (mU/mL)/405.[22] Estimated GFR was calculated
using the Chronic Kidney Disease Epidemiology Collaboration
criteria. Serum homocysteine levels were measured using the
chemiluminescent Microparticle Immuno-Assay (Abbott Architec
i2000). Elevated homocysteine was deﬁned as >13.7mmol/L.[8]
Albuminuria was deﬁned as urine ACR ≥30mg/gCr.
2.4. Statistical analysis
SPSS version 23 (IBM, Chicago, IL) was used for statistical
analyses. Data are expressed as mean± standard deviation or
frequencies (percentages). Independent t tests for continuous
variables and Pearson Chi-squared test for categorical variables
were used to compare the vitamin B12 deﬁciency group and the
normal group. Pearson correlation and linear regression analysis
were performed to ﬁnd the linear relationship between the serum
vitamin B12 levels and metformin use. Multivariate logistic
regression analysis was used to examine the factors related to
vitamin B12 deﬁciency and calculate odds ratios (OR). Area
under the curve (AUC) was measured using receiver operator
characteristic (ROC) curve analysis, and cut-off values of
duration and dose of metformin use were calculated for vitamin
B12 deﬁciency.
3. Results
The mean vitamin B12 level in the patient pool was 487.7±
260.7pg/mL. A total of 22.2% (247 patients) showed vitamin
B12 deﬁciency, with a mean vitamin B12 level of 231.2±44.8pg/
mL. In this patient pool, only 1 patient had B12 level <100pg/
mL, and 60 patients (5.4%) had serum B12 levels <200pg/mL.
Their clinical characteristics were compared with the normal-
vitamin B12 group (Table 1). Vitamin B12-deﬁcient patients were
found to have a longer duration of metformin use (11.1±7.2
years vs 9.8±6.9 years; P= .014) and took a larger dose (1558±
438mg/d vs 1276±472mg/d; P < .001) than normal patients.
Serum homocysteine was found to be signiﬁcantly greater in the
B12-deﬁcient group, at 12.8±4.7mmol/L versus 10.7±3.7mmol/
L (P= .004). Duration of diabetes, alcohol consumption, anemia,
neuropathy, multivitamin supplements (5.3% vs 20.4%; P
< .001), systolic blood pressure, AST, ALT, use of dipeptidyl
peptidase-4 inhibitors, and use of thiazolidinediones were also
signiﬁcantly different between the 2 groups. There were no
differences in age, sex, body mass index, smoking rates,
cardiovascular diseases, diabetic retinopathy, fasting glucose,
HbA1c, hemoglobin, MCV, lipid proﬁles, or GFR between the 2
groups.
Serum vitamin B12 levels showed a negative correlation with
metformin dose (r=0.300, P< .001), but were not signiﬁcantly
correlated with duration of metformin use (r=0.030, P= .317),
according to Pearson correlation. When daily metformin dose
was categorized into 4 groups as <1000, 1000 to 1500, 1500 to
2000, and ≥2000mg, serum vitamin B12 levels also signiﬁcantly
decreased as metformin dose increased (P< .001; Fig. 2).
However, when duration of metformin use was categorized as
<10, 10 to 20, and≥20 years, there was no signiﬁcant correlation
with serum vitamin B12 levels (P= .667). Even after adjusting for
multiple confounding factors using linear regression analysis, a 1
mg increase in daily metformin dose was associated with 0.142
pg/mL decrease in vitamin B12 levels (P< .001; Table 2).
Table 3 identiﬁes the potentially related factors for vitamin B12
deﬁciency. Age, sex, and other factors found to be signiﬁcant
using univariate logistic regression analysis were then used for
multivariate logistic regression analysis. Metformin dose
remained the most signiﬁcant factor related to vitamin B12
deﬁciency, even after adjusting for age, sex, duration of diabetes,
alcohol consumption, anemia, multivitamin supplementation,
ALT, and duration of metformin use. The adjusted OR was 3.34
and 8.67 for the 1500 to 2000mg group and ≥2000mg group,
respectively, compared to the group taking a daily metformin
dose <1000mg. Univariate logistic regression analysis showed
that the risk of vitamin B12 deﬁciency was signiﬁcantly increased
with duration of metformin use, where the 10 to 20 year duration
group showed an unadjusted OR of 1.50 (P= .009), and the ≥20
year group showed an unadjusted OR of 1.76 (P= .015)
compared to the <10 year group. However, the association
was not signiﬁcant after adjusting for various factors. Other than
Kim et al. Medicine (2019) 98:46 www.md-journal.com
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metformin use, factors inﬂuencing vitamin B12 deﬁciency in
patients with type 2 diabetes were alcohol consumption, anemia,
multivitamin supplements, and ALT.
Figure 3 shows the ROC curve for duration and dose of
metformin use for vitamin B12 deﬁciency. AUC for duration of
metformin use was 0.56 (95% conﬁdence interval [CI], 0.51–
0.60; P= .008), with a cut-off value of 9.5 years (sensitivity 56%,
speciﬁcity 57%). The AUC for metformin dose was 0.68 (95%
CI, 0.64–0.71; P< .001), with a cut-off value of 1425mg/day
(sensitivity 77%, speciﬁcity 48%).
Lastly, we investigated the relationship between serum vitamin
B12 levels and homocysteine levels in all patients. In multivariate
linear regression analysis, serum vitamin B12 levels showed a
signiﬁcant negative correlation with homocysteine levels even
after adjusting for various confounders, such as age, sex, duration
of diabetes, alcohol consumption, smoking, anemia, GFR,
multivitamin supplementation (beta, 13.140, P= .001). No
direct relationship was found between homocysteine levels and
the duration or dose of metformin. In the vitamin B12-deﬁcient
group, 49% showed elevated homocysteine levels, whereas in the
normal group, only 18% showed elevated homocysteine levels.
The 121 patients who showed elevated homocysteine levels in
vitamin B12-deﬁcient group were separately subjected to baseline
characteristics analysis and multivariate logistic regression
analysis, assumed as another criterion for vitamin B12 deﬁciency
(Supplemental Tables 1, http://links.lww.com/MD/D352 and 2,
http://links.lww.com/MD/D353).
4. Discussion
Our ﬁndings indicate a prevalence of vitamin B12 deﬁciency of
22.2% in patients with type 2 diabetes taking long-term
metformin, with larger daily doses signiﬁcantly associated with
vitamin B12 deﬁciency. Factors other than metformin dose
associated with vitamin B12 deﬁciency were age, alcohol
consumption, anemia, multivitamin supplements, and ALT
levels. Unexpectedly, the duration of metformin use did not
show signiﬁcant association with vitamin B12 deﬁciency. Serum
homocysteine levels showed a signiﬁcant negative correlation
with serum vitamin B12 levels as well as signiﬁcant differences
between the vitamin B12-deﬁcient and normal groups. In the
vitamin B12-deﬁcient group, 49% of patients showed concur-
rently elevated homocysteine levels, suggesting true tissue
deﬁciency.
The “golden standard” for deﬁning vitamin B12 deﬁciency is
not yet established, since there are various methods for measuring
serum vitamin B12, corresponding normal values, and research
results. One study reporting lower speciﬁcity showed that 60%of
patients had symptoms of vitamin B12 deﬁciency when B12 level
was <200pg/mL, and 90% at <100pg/mL.[23] In general;
however, serum vitamin B12 levels can be interpreted as follows:
>300pg/mL, B12 deﬁciency is unlikely (probability of 1%–5%);
200 to 300pg/mL, B12 deﬁciency possible (probability of 5%–
15%); <200pg/mL, consistent with B12 deﬁciency (speciﬁcity of
90%–100%).[1,20,24] On this basis, biochemical vitamin B12
deﬁciency was deﬁned as serum B12 <300pg/mL, not accompa-
nied by serum folic acid deﬁciency, in this study.[1,20] In other
studies, it was recommended that other metabolites, such as
homocysteine or methylmalonic acid (MMA), be measured
together since it is difﬁcult to deﬁne true vitamin B12 deﬁciency as
serum vitamin B12 levels alone.[25,26] If homocysteine andMMA
are elevated along with the low vitamin B12 values, it is explained
that they have 85% to 98% sensitivities.[20,26] Although MMA
values were not measured, serum homocysteine values were
measured in this study. Therefore, the deﬁnition of vitamin B12
Table 1
Clinical characteristics of the study population.
Vitamin B12
deﬁciency
Normal
vitamin B12 P-value
Number (%) 247 (22.2) 864 (77.8)
Age, yr 60.1±11.6 59.3±10.7 .291
Male (%) 148 (59.9) 497 (57.5) .501
Diabetes duration, yr 11.4±7.0 10.2±6.9 .019
BMI, kg/m2 26.4±5.2 26.0±3.6 .215
Alcohol > 98 g/wk (%) 60 (24.6) 157 (18.6) .041
Current smoker (%) 49 (20.7) 168 (20.4) .936
Cardiovascular disease
∗
(%) 45 (18.2) 119 (13.8) .082
Diabetic retinopathy (%) 44 (23.3) 128 (19.6) .265
Systolic BP, mm Hg 130.1±12.6 128.4±12.3 .047
Diastolic BP, mm Hg 78.0±10.1 76.9±9.4 .090
Hypertension (%) 179 (72.5) 574 (66.7) .085
Anemia† (%) 48 (19.4) 117 (13.6) .022
Neuropathy‡ (%) 67 (28.0) 179 (21.4) .031
Fasting glucose, mg/dL 139.4±36.6 138.7±37.3 .791
Hemoglobin A1c (%) 7.1±0.9 7.2±1.0 .167
HOMA-IR 1.1±0.9 1.2±2.5 .763
Hemoglobin, g/dL 13.6±1.6 13.8±1.7 .053
MCV, fL 90.4±4.7 91.7±29.9 .504
Total cholesterol, mg/dL 144.5±27.0 146.5±25.7 .285
Triglyceride, mg/dL 138.8±70.8 137.5±70.6 .800
HDL-cholesterol, mg/dL 45.6±10.5 46.0±10.8 .612
LDL-cholesterol, mg/dL 76.4±24.3 77.6±21.9 .466
AST, IU/L 25.4±10.7 28.2±12.7 .001
ALT, IU/L 23.4±13.4 28.2±16.5 <.001
Creatinine, mg/dL 0.98±0.48 0.95±0.23 .389
eGFR, mL/min/1.73 m2 79.7±17.0 80.4±17.1 .587
uACR ≥30mg/mg Cr (%) 54 (22.8) 193 (23.3) .967
Vitamin B12, pg/mL 231.2±44.8 561.0±250.3 <.001
Folate, ng/mL 13.0±4.5 14.7±11.1 .440
Homocysteine, mmol/L 12.8±4.7 10.7±3.7 .004
Multivitamin agents (%) 13 (5.3) 158 (20.4) <.001
Calcium supplement (%) 17 (6.9) 67 (7.8) .648
H2 blocker or PPI (%) 21 (8.5) 85 (9.8) .529
Thiazolidinediones (%) 26 (10.5) 54 (6.3) .022
Sulfonylurea (%) 96 (38.9) 284 (32.9) .080
DPP-4 inhibitor (%) 185 (74.9) 528 (61.1) <.001
SGLT-2 inhibitor (%) 28 (11.3) 121 14.0) .275
Insulin use (%) 27 (10.9) 129 (14.9) .111
Metformin duration, yr 11.1±7.2 9.8±6.9 .014
<10 110 (44.5) 480 (55.6) .007
10–<20 104 (42.1) 302 (35.0)
≥20 33 (13.4) 82 (9.5)
Metformin dose, mg/d 1558±438 1276±472 <.001
<1000 21 (8.5) 202 (23.4) <.001
1000–<1500 37 (15.0) 215 (24.9)
1500–<2000 114 (46.2) 341 (39.5)
≥2000 75 (30.4) 106 (12.3)
Data are presented as mean± standard deviation (SD) or number (%).
ACR= albumin-to-creatinine ratio, ALT= alanine aminotransferase, AST= aspartate aminotransfer-
ase, BMI=body mass index, BP=blood pressure, DPP-4=dipeptidyl peptidase-4, fL= femtolite,
GFR=glomerular ﬁltration rate, H2 blocker=histamine 2 receptor blocker, HDL=high-density
lipoprotein, HOMA-IR= the homeostasis model of assessment-insulin resistance, LDL= low-density
lipoprotein, MCV=mean corpuscular volume, PPI=proton pump inhibitor, SGLT-2= sodium glucose
co-transporter-2.
∗
Having recorded percutaneous coronary intervention or coronary bypass surgery, percutaneous
transluminal angioplasty for peripheral arterial occlusive disease, or stroke, conﬁrmed by a neurologist.
† Hemoglobin <13g/dL for men, <12g/dL for women (WHO guidelines).
‡ Previous neuropathy was diagnosed, or MNSI >2.
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deﬁciency was secondarily deﬁned as vitamin B12 <300pg/mL
and homocysteine >13.7mmol/L,[8] and once again analysis was
performed. There was no difference in overall results, both when
247 patients with only low serum vitamin B12 levels were deﬁned
as vitamin B12 deﬁciency, and 121 patients with low vitamin B12
and high homocysteine values were deﬁned as vitamin B12
deﬁciency.
The prevalence of vitamin B12 deﬁciency after metformin use
has been reported to be 6% to 30%, varying with race, standard
values of vitamin B12, and metformin usage.[3–10] A large
prospective study reported a 20.3% prevalence of vitamin B12
deﬁciency after 9.5 years of metformin use,[10] and a large dataset
provided by the National Health and Nutrition Examination
Survey showed a 22% prevalence when vitamin B12 deﬁciency
was deﬁned as levels below 300pg/mL.[3] A recent study of 799
patients by the College of Medicine of the Catholic University of
Korea showed a lower prevalence of vitamin B12 deﬁciency
(9.5%) and highermean B12 levels (662.5±246.7 pg/mL) than in
the present study. The reasons for the difference may include
differences in testing methods, differences in alcohol consump-
tion, and differences in the doses of metformin use.[6] Some
studies have focused on the impact of the duration and doses of
Figure 2. Box plot for serum vitamin B12 level according to different dose of metformin. (P for trend <.001).
Table 2
Relationship between metformin use and serum vitamin B12 level.
Metformin duration Metformin dose
Beta (95% CI) P-value Beta (95% CI) P-value
Serum vitamin B12
Crude 0.030 (1.074, 3.314) .317 0.299 (0.193, 0.132) <.001
Model 1 0.913 (10.595, 8.769) .853 0.159 (0.191, 0.126) <.001
Model 2 5.289 (2.509, 13.314) .183 0.142 (0.169, 0.114) <.001
Multivariable logistic regression analysis models were adjusted as follows: model 1: sex, age, diabetes duration; model 2: model 1 + duration of metformin, daily dose of metformin, alcohol, presence of anemia,
multivitamin agents, ALT.
CI= conﬁdence interval.
Table 3
Logistic regression for the potentially related factors of vitamin
B12 deﬁciency among patients with type 2 diabetes.
Risk factors OR (95% CI) P-value
Age, per yr 1.02 (1.00–1.04) .019
Male 0.98 (0.68–1.41) .912
Diabetes duration 0.98 (0.93–1.03) .330
Alcohol >98 g/wk 1.75 (1.15–2.66) .009
Anemia
∗
1.56 (1.00–2.41) .048
Multivitamin agents 0.23 (0.13–0.42) <.001
ALT, IU/L 0.98 (0.96–0.99) .008
Metformin duration .386
<10, yr 1
10–<20 1.43 (0.86–2.37) .169
≥20 1.86 (0.62–5.55) .267
Metformin dose <.001
<1000, mg/d 1
1000–<1500 1.72 (0.94–3.14) .080
1500–<2000 3.34 (1.95–5.75) <.001
≥2000 8.67 (4.68–16.06) <.001
ALT= alanine aminotransferase, CI= conﬁdence interval, OR= odds ratio.
∗
Hemoglobin <13g/dL for men, <12g/dL for women (WHO guidelines).
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metformin on vitamin B12 deﬁciency. In the previously
mentioned study, both the duration and daily dose of metformin
were signiﬁcantly associated with vitamin B12 deﬁciency, with
cut-off values of 4 years and 1100mg/d, respectively.[6] In
another study, metformin dose had a negative relationship with
vitamin B12 levels, and an increase of 1mg in the daily metformin
dose was associated with a 0.042pg/mL decrease in vitamin B12
levels, but the duration of metformin use did not show signiﬁcant
effects.[5] Similarly, several further studies have reported that
daily dose is a more strongly associated with vitamin B12
deﬁciency than duration.[27,28] Our ﬁndings indicate that a 1mg/
d increase in metformin dose decreased vitamin B12 levels by
0.142pg/mL, but the duration of use did not have signiﬁcant
effects. Altogether, the results of these studies and our study
indicate that it is important to account for metformin dose in
recommendations for screening for vitamin B12 deﬁciency, and
not just the duration of metformin use.
Vitamin B12 is involved in the activity of methylmalonyl-CoA
mutase and the pathway for methionine synthase in cells.
Intracellular vitamin B12 deﬁciency interferes with both of these
pathways and increases MMA and homocysteine, which are
biochemical indicators of metabolic efﬁcacy.[13,17] Therefore, if a
decrease in serum vitamin B12 levels is not accompanied by an
increase in MMA and homocysteine levels, this could be
interpreted as a simple plasma decrease of vitamin B12 levels,
rather than a true tissue deﬁciency. In fact, some studies have
reported that decreases in vitamin B12 after metformin treatment
were only plasma decreases, without an increase in homocysteine
levels.[29–31] Leung et al suggested that metformin only reducted
the level of non-functional plasma B12, the part bound to
haptocorrin, and not the active part bound to transcobalamin.[31]
According to Greibe’s study, plasma vitamin B12 decreased by
22% in rats treated with metformin, whereas the total vitamin
B12 in tissues and organs did not decrease, and B12 accumulation
in the liver was observed.[29] However, other studies have found
that patients taking metformin had decreased vitamin B12 levels
as well as increased homocysteine levels, suggesting true tissue
deﬁciency, and a consensus has not yet been reached.[9] In the
present study, serum homocysteine levels showed signiﬁcant
negative correlation with serum B12 levels as well as signiﬁcant
differences between the vitamin B12-deﬁcient and normal
groups. In addition, 49% of patients in the vitamin B12-deﬁcient
group showed concurrently elevated homocysteine levels,
whereas in the normal group, only 18% showed elevated
homocysteine levels. This result supports the hypothesis that
vitamin B12 decreases due tometformin use indicate a decrease at
the tissue level. Of course, measurement of additional markers,
such as holotranscobalamin, MMA, red blood cell-B12, and
plasma concentrations of methylation indices may provide a
more comprehensive assessment of true deﬁciency, but are
beyond the scope of this study.[32] A large prospective study
measuring more functional markers is needed to ensure support
for this hypothesis.
The clinical signiﬁcance of vitamin B12 deﬁciency lies in
megaloblastic anemia and neuropathy.[1,16,17] In this study,
anemia was a signiﬁcant factor related to B12 deﬁciency, even
after adjusting for other confounders; but in other studies, there
were few patients with typical megaloblastic anemia (MCV>100
fL).[6] In all, 13 patients showed MCV >100 fL, and only 1 was
vitamin B12-deﬁcient. This may be because various factors, such
as age and nutrition, play parts in vitamin B12 deﬁciency, along
with other factors, such as iron deﬁciency anemia and anemia due
to chronic disease. This result is supported by other studies which
found that 30% of patients, even those with anemia due to
vitamin B12 deﬁciency, had normalMCVs.[33–35] Since this study
followed a cross-sectional design, we cannot judge the causal
relationship, but our results indicate vitamin B12 deﬁciency
affected anemia.
Figure 3. Receiver operator characteristic curve analysis for period of metformin use and daily metformin dose related to vitamin B12 deﬁciency.
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Neuropathy due to metformin-induced vitamin B12 deﬁciency
has been studied and reported numerous times, but causal
relationships remain unclear. As has been recently reported,
vitamin B12 deﬁciency due tometformin use maybe not related to
neuropathy if it is a simple plasma deﬁciency.[17] Differences in
the prevalence of neuropathy between the B12-deﬁcient group
and the normal group in this study were statistically signiﬁcant,
but there was no signiﬁcant relationship between vitamin B12
deﬁciency and neuropathy after adjusting for various factors.
Although it is nearly impossible to clinically distinguish
neuropathy caused by vitamin B12 deﬁciency from diabetic
neuropathy, neuropathy should still be closely monitored, since
early diagnosis and treatment improve prognosis.[1]
The mechanism by which metformin reduces serum vitamin
B12 levels has not been elucidated, but the most likely hypothesis
is that metformin interferes with calcium-dependent membrane
action responsible for vitamin B12 intrinsic factor absorption in
the terminal ileum.[36] Few studies have investigated whether
such absorption difﬁculties caused by metformin could be
improved by supplementation of multivitamins, which usually
contain small amounts of vitamin B12 at 2 to 30ug/d. A recent
review paper recommended the use of vitamin supplements for
patients on long-term metformin treatment to prevent decreases
in vitamin B12, albeit without direct evidence.[37] Moreover, a
retrospective study showed that among metformin users,
multivitamin use was associated with lower prevalence of
vitamin B12 deﬁciency (adjusted OR=0.14; 95% CI=0.04,
0.54) compared to those not usingmultivitamins.[38] However, in
most other studies that investigated the supplementation with
multivitamins, no signiﬁcant inﬂuence on vitamin B12 deﬁciency
was observed.[3,6,28] In the present study, the mean vitamin B12
level in patients taking multivitamin was 715.1±340.4pg/mL,
and that in patients who did not take multivitamin was 410.8±
173.4pg/mL (P< .001). After adjusting for various confounders,
our ﬁndings indicate that multivitamin supplementation was
signiﬁcantly associated with lower prevalence of vitamin B12
deﬁciency and a reduced OR of developing a deﬁciency. We
suggest that results with such a meaningful difference were
derived, as the study investigated and compared patients whose
records showed that they had regularly consumed vitamin
supplements for more than 6 months. However, the lack of a
detailed grasp of the vitamin B12 dose contained in multivitamin
is one of the major limitations of our study. Further well-designed
studies should be conducted to conﬁrm the validity of
multivitamin use for preventing B12 deﬁciency.
The strength of this study lies in the large sample population,
especially of Asian people on whom little research has been
conducted. We also observed the effect of duration and dose of
metformin on vitamin B12 deﬁciency; moreover, this study
examined more related factors (neuropathy symptoms, homo-
cysteine levels, multivitamin use, etc) than did previous studies.
We further deﬁned vitamin B12 deﬁciency as a group with both
serum vitamin B deﬁciency and homocysteine elevation, and
compared it to the group lacking only serum vitamin B12
additionally. However, this study had several limitations in
addition to a number of aforementioned issues. First, the cross-
sectional study approach could not probe the causal relationship
between various factors and vitamin B12 deﬁciency. Second, it is
possible that our record was insufﬁcient to capture an accurate
representation of patients with a very long period of metformin
use, or who had changed their hospital. Therefore, information
on the duration of metformin use was dependent on patients’
memories, and the information could have been inaccurate.
Third, daily metformin doses were determined by calculating the
average of the most recent 6 months, and did not cover the entire
duration of metformin use. Because this study was not
prospective, there was insufﬁcient information to accurately
calculate the cumulative dose during the total period of
metformin use. Fourth, animal foods such as meat, ﬁsh, and
dairy products are rich in vitamin B12. Therefore, to reduce the
confounding parameters, patients’ diets should be investigated.
However, we could not obtain detailed information on the
matter, and only ascertained whether a patient was a vegetarian
or not. Lastly, our study relied only on subjective symptoms of
the patients for diagnosis of neuropathy, without conducting
dedicated neurological examinations that could give objective
results; as such, this may have led to an increase in false-negative
results.
5. Conclusion
We found that the use of metformin at doses equal to or greater
than 1500mg/d is a major factor related to the development of
vitamin B12 deﬁciency, and that concurrent supplementation of
multivitamins may potentially protect against this. Serum
homocysteine levels were negatively correlated with vitamin
B12 levels, suggesting that the B12 deﬁciency observed due to use
of metformin occurred at the tissue level, but this hypothesis
needs further study.
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